Clinical Trial Detail

NCT ID NCT02926690
Title Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors OncoTherapy Science, Inc.
Indications

triple-receptor negative breast cancer

breast cancer

Therapies

OTS167

Age Groups: adult senior

No variant requirements are available.